Citations

Clear

4093 citation(s) found for "Yu, Jonathan".

Major adverse cardiovascular events after diagnosis of myocardial injury and types 1 and 2 myocardial infarction
Knott, Jonathan D , Ola, Olatunde , Akula, Ashok , Mehta, Ramila A. , Dworak, Marshall , Crockford, Erika, Lobo, Ronstan , Rastas, Nicholas, Karturi, Swetha, Wohlrab, Scott, Hodge, David O. , Grube, Eric , Tak, Tahir , Cagin, Charles , Gulati, Rajiv , Jaffe, Allan S. , Sandoval, Yader , Sandoval, Yader , Michieli, Laura De , Grube, Eric, Jaffe, Allan S.

Mayo Clinic

European Heart Journal. Acute Cardiovascular Care | June 18, 2022 | Volume: 11 | Issue: 7 | Pages: 546-557

10.1093/ehjacc/zuac075 | PMID 35715942 Get It

Abstract Aims Limited US outcome data exist among patients with myocardial injury and types 1 and 2 myocardial infarction (MI) evaluated with high-sensitivity cardiac troponin (hs-cTn). Methods and results This is an observational US cohort study of emergency department (ED) patients undergoing hs-cTnT measurement. Cases with ≥1 hs-cTnT increase >99th percentile were adjudicated following the Fourth Universal Definition of MI. Post-discharge major adverse cardiovascular events (MACE) included death, MI, heart failure (HF) hospitalization, stroke or transient ischaemic attack, and new-onset atrial fibrillation or flutter during 2 years follow-up. Among 2002 patients, 857 (43%) had ≥1 hs-cTnT >99th percentile. Among these, 702 (81.9%) had myocardial injury, 64 (7.5%) had type 1 MI, and 91 (10.6%) had type 2 MI. Compared with patients without myocardial injury, type 2 MI [8.4 vs. 50%; adjusted hazard ratio (HR) 2.31, 95% confidence interval (CI) 1.49–3.58] and myocardial injury (8.4 vs. 47%; adjusted HR 3.13, 95% CI 2.39–4.09) had a higher risk of MACE, in large part because of death and HF hospitalizations. Compared with patients with type 1 MI, type 2 MI (23 vs. 50%; adjusted HR 2.24; 95% CI 1.23–4.10) and myocardial injury (23 vs. 47%; adjusted HR 2.02; 95% CI 1.20–3.40) also have a higher risk of MACE. Conclusion Among unselected US ED patients undergoing hs-cTnT measurement, most increases are due to myocardial injury, and type 2 MI is more frequent than type 1 MI. Patients with myocardial injury and type 2 MI have morbid outcomes, in large part due to death and HF.
Abstract 3092: Urine-derived urinary carcinoma organoids: A novel tool for providing new insights into human and canine bladder cancer treatment
Sahoo, Dipak Kumar , Mosichuk, Allison P., Frank, Igor, Cheville, John C. , Mochel, Jonathan P. , Sahoo, Dipak K , Mochel, Jonathan P , Lucien, Fabrice , Allenspach, Karin

Mayo Clinic

Cancer Research | June 15, 2022 | Volume: 82 | Issue: 12_Supplement | Pages: 3092-3092

10.1158/1538-7445.am2022-3092 Get It

Abstract The outcome of patients with Muscle Invasive Bladder Cancer (MIBC) is highly variable with many patients experiencing progressive disease despite multimodal therapy. A key variable that contributes to poor patient outcomes lies in our inability to predict therapeutic response due to the molecular heterogeneity of MIBC tumors. There is, therefore, a significant unmet clinical need to accurately predict effective drug combinations and therapeutic doses in individual patients with MIBC. Patient-derived tumor organoids (PDOs) have the potential to serve as an ex vivo model of urothelial carcinoma (UC) capable of functionally predicting patient-specific treatment responses. However, current culture procedures typically rely on the expansion of UC organoids from resected tumors or biopsy specimens, which is inherently invasive and hence limits clinical application. We hypothesized that culture of MIBC PDOs can be achieved from urine samples, as is the case in dogs with MIBC, since histopathological features, tumor heterogeneity and subtypes, metastatic activity, and gene expression profiles of canine MIBC mimic those of human MIBC. Herein, we successfully cultured MIBC organoids from both human and canine patients using first-catch urine. Briefly, after centrifuging urine samples to pellet cells, the cells were washed with basal culture media containing FBS and Pen/Strep before being cultured in canine or human culture media containing essential growth factors based on their species of origin. Paraffin-embedded samples were used for molecular characterization by RNA in situ hybridization or immunohistochemistry. Organoids from canine MIBC patients were analyzed for expression of the urothelial differentiation marker (FOXA1) associated with high grade bladder cancer, CD44, a non-kinase transmembrane glycoprotein expressed in UC cancer stem cells, and CK7, an epithelial cell marker that is upregulated in neoplastic UC cells. FOXA1 expression was undetectable in canine MIBC, although CD44 expression was enhanced compared to healthy dog bladder organoids. All canine MIBC organoids had significantly enhanced CK7 expression. Similarly, in human-derived UC organoids, GATA binding protein 3 (GATA3), transcription factor paired box 8 (Pax8), and tumor protein p63 were utilized as markers, with a Pax8-/p63+/GATA3+ profile indicating UC origin of the organoids. Functional response to chemotherapy (cisplatin and gemcitabine) was further assessed using cell viability assay in canine and human UC organoids. Our data suggest that organoids cultured from the urine of patients with MIBC can recapitulate organ structures and maintain marker expression profiles of the original tumor tissues. 3D organoids may provide novel insights to predict therapeutic response to chemotherapy and serve as early diagnostic biomarkers of bladder cancer in both canine and human patients. Citation Format: Dipak Kumar Sahoo, Allison P. Mosichuk, Fabrice Lucien, Igor Frank, John C. Cheville, Karin Allenspach, Jonathan P. Mochel. Urine-derived urinary carcinoma organoids: A novel tool for providing new insights into human and canine bladder cancer treatment [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 3092.
Abstract CT251: LuMIERE: A phase 1/2 study investigating safety, pharmacokinetics, dosimetry, and preliminary antitumor activity of 177Lu-FAP-2286 in patients with advanced or metastatic solid tumors
Dhawan, Mallika, Goenka, Ajit H. , Chasen, Beth, Khushman, Moh’d, Mintz, Akiva , Bowles, Owen, Simmons, Andrew D. , Wride, Kenton, Enke, Aaron, McConathy, Jonathan , Lim, Emerson A. , Menda, Yusuf , Zakharia, Yousef , Sunderland, John J. , Xiao, Jim J. , Hope, Thomas A.

Mayo Clinic

Cancer Research | June 15, 2022 | Volume: 82 | Issue: 12_Supplement | Pages: CT251-CT251

10.1158/1538-7445.am2022-ct251 Get It

Abstract Background: Fibroblast activation protein (FAP) is a membrane-bound protease that is highly expressed on the surface of cancer-associated fibroblasts (CAFs) present in the tumor microenvironment of most epithelial cancers. With limited expression observed in normal tissues, FAP is a promising therapeutic and imaging target for delivery of radionuclides to cancer tissues. FAP-2286, a low-molecular-weight cyclic peptide that potently and selectively binds to FAP, is attached to a linker and tetraazacyclododecane tetraacetic acid (DOTA) cage that can be used to conjugate radionuclides such as lutetium-177 (177Lu) or gallium-68 (68Ga) for therapeutic or imaging applications, respectively. 177Lu-FAP-2286 has demonstrated antitumor activity in preclinical studies. The LuMIERE study (NCT04939610) is the first phase 1/2 clinical trial of an FAP-targeted radionuclide therapy evaluating 177Lu-FAP-2286 in patients with FAP-expressing solid tumors that are identified with the imaging agent 68Ga-FAP-2286. Methods: Eligible adult patients with advanced or metastatic solid tumors and measurable disease (per RECIST v1.1) will be selected for treatment with 177Lu-FAP-2286 on the basis of FAP expression using 68Ga-FAP-2286. In phase 1, tumors must be refractory to or have progressed following prior treatment, with no satisfactory alternative treatment options. Phase 1 includes dose escalation of 177Lu-FAP-2286, starting at 3.7 GBq to a maximum of 9.25 GBq. Patients may receive up to 6 cycles of 177Lu-FAP-2286 administered on day 1 of each 6-week cycle. Three to 12 patients will be treated at each dose level in the dose-escalation portion. Tolerability will be assessed across multiple doses for determination of a recommended phase 2 dose (RP2D), which may be further evaluated in a phase 1 dose-expansion portion. FDG-PET/CT scans will be collected prior to treatment, and patients will be imaged by planar and SPECT/CT scans at multiple time points to calculate organ and tumor dosimetry to determine absorbed radiation dose. Disease status will be assessed per RECIST v1.1 every 6 weeks. The primary objective of phase 1 is to evaluate the safety of 177Lu-FAP-2286 and determine the RP2D. Secondary objectives include the assessment of radiation dosimetry, pharmacokinetics, and preliminary efficacy of 177Lu-FAP-2286 and the evaluation of safety and tumor uptake of 68Ga-FAP-2286. Phase 2 will evaluate the efficacy, safety, and dosimetry of 177Lu-FAP-2286 in patients with select FAP-expressing solid tumors. Citation Format: Jonathan McConathy, Mallika Dhawan, Ajit H. Goenka, Emerson A. Lim, Yusuf Menda, Beth Chasen, Moh'd Khushman, Akiva Mintz, Yousef Zakharia, John J. Sunderland, Owen Bowles, Jim Xiao, Andrew D. Simmons, Kenton Wride, Aaron Enke, Thomas A. Hope. LuMIERE: A phase 1/2 study investigating safety, pharmacokinetics, dosimetry, and preliminary antitumor activity of 177Lu-FAP-2286 in patients with advanced or metastatic solid tumors [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr CT251.
Three-Dimensional Modeling for Augmented and Virtual Reality–Based Posterior Fossa Approach Selection Training: Technical Overview of Novel Open-Source Materials
Graffeo, Christopher S. , Perry, Avital , Nguyen, Bachtri T. , Alexander, Amy E. , Holroyd, Michael J., Peris‐Celda, Maria , Driscoll, Colin L. W., Link, Michael J., Carlstrom, Lucas P. , Nguyen, Bachtri , Link, Michael J. , Morris, Jonathan M.

Mayo Clinic

Operative Neurosurgery | June 15, 2022 | Volume: 22 | Issue: 6 | Pages: 409-424

10.1227/ons.0000000000000154 | PMID 35867081 Get It

BACKGROUND: Selection of skull base approaches is a critical skill for complex cranial surgery, which demands nuanced understanding of neuroanatomy and pathology. OBJECTIVE: To develop novel pedagogical resources for approach selection education and assessment. METHODS: A prospectively maintained skull base registry was screened for posterior fossa tumors amenable to 3-dimensional (3D) modeling of multiple operative approaches. Inclusion criteria were high-resolution preoperative and postoperative computed tomography and MRI studies (≤1 mm) and consensus that at least 3 posterior fossa craniotomies would provide feasible access. Cases were segmented using Mimics and modeled using 3-Matic. Clinical Vignettes, Approach Selection Questionnaire, and Clinical Application Questionnaire were compiled for implementation as a teaching/testing tool. RESULTS: Seven cases were selected, each representing a major posterior fossa approach group. 3D models were rendered using clinical imaging for the primary operative approach, as well as a combination of laboratory neuroanatomic data and extrapolation from comparable craniotomies to generate 2 alternative approaches in each patient. Modeling data for 3D figures were uploaded to an open-sourced database in a platform-neutral fashion (.x3d) for virtual/augmented reality and 3D printing applications. A semitransparent model of each approach without pathology and with key deep structures visualized was also modeled and included for comprehensive understanding. CONCLUSION: We report a novel series of open-source 3D models for skull base approach selection training, with supplemental resources. To the best of our knowledge, this is the first such series designed for pedagogical purposes in skull base surgery or centered on open-source principles.
Abstract 1192: The Clinical Genome Resource (ClinGen) somatic cancer clinical domain working group
Raca, Gordana , Roy, Angshumoy , Xu, Xinjie , Satgunaseelan, Laveniya , Church, Alanna J. , Terraf, Panieh, Akkari, Yassmine, Williams, Heather , Lin, Wan‐Hsin , Ritter, Deborah , Krysiak, Kilannin, Danos, Arpad , Kulkarni, Shashikant , CDWG, on behalf of the ClinGen Somatic, Satgunaseelan, Laveniya , Saliba, Jason , King, Ian F. G. , Selvarajah, Shamini , Kanagal‐Shamanna, Rashmi , Meredith, David M. , Evans, Mark G. , Williams, Heather E., Kesserwan, Chimene A. , Wagner, Alex H. , Li, Marilyn M , Sonkin, Dmitriy , Berg, Jonathan S. , Plon, Sharon E. , Rehm, Heidi L. , Govindan, Ramaswamy , Griffith, Obi L. , Griffith, Malachi , CDWG, on behalf of the ClinGen Somatic

Mayo Clinic

Cancer Research | June 15, 2022 | Volume: 82 | Issue: 12_Supplement | Pages: 1192-1192

10.1158/1538-7445.am2022-1192 Get It

Abstract Interpretation of the clinical significance of somatic gene variants in cancer remains a major challenge in cancer diagnosis, prognosis and treatment response prediction. We will report on progress and plans of the Clinical Genome Resource (ClinGen) Somatic Cancer Clinical Domain Working Group (CDWG). The CDWG membership consists of over 150 multi-disciplinary experts in cancer biology, oncology, pathology, genetics, genomics and informatics. The mission of the ClinGen Somatic Cancer CDWG is to facilitate the development of data curation guidelines and standards to determine the clinical significance of somatic alterations in cancer, thereby enhancing the usability, dissemination and implementation of cancer somatic changes in the ClinGen resource and other knowledgebases including CIViC, ClinVar, and the Variant Interpretation for Cancer Consortium (VICC) MetaKB. Our goal is to create high-quality assertions of the clinical significance of specific somatic variants in cancer by leveraging the CIViC curation interface, adapting the germline procedures of ClinGen to somatic variant interpretation, and implementing the interoperability standards of the Global Alliance for Genomics and Health (GA4GH). The ClinGen Somatic effort is overseen by the Somatic CDWG and reports progress to the overall ClinGen consortium. There are Somatic Cancer subdomains focused on particular clinically important domains of cancer variant interpretation including three Task Forces (covering Pediatric Cancer, Hematologic Cancer, and Solid Tumors) and a growing number of Somatic Cancer Variant Curation Expert Panels (SC-VCEPs). To improve quality and consistency of clinical interpretations, each candidate somatic cancer VCEP must complete a four step approval process adapted from ClinGen’s work in Germline disease domains. The Somatic CDWG works to ensure that each group is aware of available training materials and detailed standard operating procedures. Each SC-VCEP also coordinates with the ClinGen Cancer Variant Interpretation Committee (CVI) whose goal is to support development of granular specifications for the AMP/ASCO/CAP guidelines for somatic variant interpretation. New SC-VCEPs are anticipated to focus on specific clinically relevant genes, pathways, disease entities, variant classes or treatment modalities. Currently, three SC-VCEPs have begun to work through the four step process (focused on FGFR mutations, NTRK fusions, and FLT3 mutations respectively), and two more SC-VCEPs are in the planning stage (Histone H3 and Ph-like ALL). To date, ClinGen Somatic groups have contributed 619 evidence lines into CIViC from 353 published papers and 21 assertions of clinical significance. Input from the AACR community is critical for the establishment of new SC-VCEPs that address areas of variant interpretation with the greatest need. Citation Format: Jason Saliba, Gordana Raca, Angshumoy Roy, Ian King, Shamini Selvarajah, Xinjie Xu, Rashmi Kanagal-Shamanna, Laveniya Satgunaseelan, David Meredith, Mark Evans, Alanna Church, Panieh Terraf, Yassmine Akkari, Heather E. Williams, Wan-Hsin Lin, Chimene Kesserwan, Deborah I. Ritter, Kilannin Krysiak, Arpad Danos, Alex Wagner, Marilyn M. Li, Dmitriy Sonkin, Jonathan S. Berg, Sharon E. Plon, Heidi L. Rehm, Shashikant Kulkarni, Ramaswamy Govindan, Obi L. Griffith, Malachi Griffith, on behalf of the ClinGen Somatic CDWG. The Clinical Genome Resource (ClinGen) somatic cancer clinical domain working group [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 1192.
Minimum Technical Requirements for Performing Ambulatory EEG
Tatum, William O. , Halford, Jonathan J. , Olejniczak, Piotr W., Selioutski, Olga , Grigg‐Damberger, Madeleine , Gloss, David , Acharya, Jayant N. , Tsuchida, Tammy N., Drislane, Frank W. , Halford, Jonathan J , Selioutski, Olga , Schuele, Stephan , Sinha, Saurabh R.

Mayo Clinic

Journal of Clinical Neurophysiology | June 15, 2022 | Volume: 39 | Issue: 6 | Pages: 435-440

10.1097/wnp.0000000000000950 | PMID 35916885 Get It

Summary: Ambulatory EEG (AEEG) devices offer portable, multichannel, digital EEG recording with or without video in the patient's natural environment. The technology applied for AEEG recording is like the technology for routine EEG and inpatient long-term video-EEG monitoring but designed to be compact and wearable. Computer-based AEEG technology is well-suited to digital recording, signal processing, and visual display. However, acquiring interpretable EEG outside of the hospital setting presents its own technical challenges. Published guidelines have established technical standards for performing routine EEG and inpatient video-EEG monitoring, but technical standards for AEEG are lacking. Therefore, this guideline provides minimal technical standards for the performance of AEEG which are essential to ensure the quality of studies for clinical and research practice. We expect these minimum standards to evolve over time with improved performance and advances in the technology.
Does a Multiple Myeloma Polygenic Risk Score Predict Overall Survival of Patients with Myeloma?
Macauda, Angelica , Clay‐Gilmour, Alyssa , Hielscher, Thomas , Kruszewski, Marcin , Orlowski, Robert Z. , Kumar, Shaji , Ziv, Elad , Brown, Elizabeth E. , Waller, Rosalie G. , Machiela, Mitchell J. , Camp, Nicola J. , Raźny, Małgorzata , Várkonyi, Judit , Piredda, Chiara , Pelosini, Matteo , Belachew, Alem A. , Rybicka‐Ramos, Malwina, Goldschmidt, Hartmut , Tomczak, Waldemar , Sáinz, Juan , Butrym, Aleksandra , Wątek, Marzena , Iskierka‐Jazdzewska, Elżbieta , Buda, Gabriele , Robinson, Dennis P. , Dudziński, Marek , Martínez‐López, Joaquín , Reis, Rui Manuel , Weinhold, Niels , Bhatti, Parveen , Carvajal‐Carmona, Luis G. , Zawirska, Daria , Mazur, Grzegorz , Berndt, Sonja I. , Campa, Daniele , Vachon, Celine M. , Martinez-Lopez, Joaquin , Griffin, R. L. , Kruszewski, Marcin , Orlowski, Robert Z. , Kumar, Shaji K , Ziv, Elad , Försti, Asta , Waller, Rosalie G , Machiela, Mitchell J , Chanock, Stephen Jacob , Camp, Nicola J , Rymko, Marcin , Raźny, Małgorzata , Cozen, Wendy , Piredda, Chiara , Pelosini, Matteo , Belachew, Alem A , Subocz, Edyta , Giles, Graham G , Milne, Roger L , Zaucha, Jan Maciej , Vangsted, Annette Juul , Goldschmidt, Hartmut , Rajkumar, S Vincent , Tomczak, Waldemar , Sainz, Juan , Watek, Marzena , Iskierka-Jazdzewska, Elżbieta , Buda, Gabriele , Dudziński, Marek , Martinez-Lopez, Joaquin , Sinnwell, Jason P , Slager, Susan L , Reis, Rui Manuel , Weinhold, Niels , Bhatti, Parveen , Carvajal-Carmona, Luis G , Zawirska, Daria , Mazur, Grzegorz , Berndt, Sonja I , Vachon, Celine M. , Canzian, Federico , Martinez-Lopez, Joaquin , Butrym, Aleksandra , Griffin, Rosalie , Hildebrandt, Michelle A.T. , Orciuolo, Enrico , Försti, Asta , Rymko, Marcin , Cozen, Wendy , Subocz, Edyta , Hemminki, Kari , Giles, Graham G. , Milne, Roger L. , Hofmann, Jonathan N. , Zaucha, Jan Maciej , Rajkumar, S. Vincent , Jurczyszyn, Artur , Sinnwell, Jason P. , Slager, Susan L. , Jamroziak, Krzysztof , Norman, Aaron D. , Canzian, Federico

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | June 14, 2022 | Volume: 31 | Issue: 9 | Pages: 1863-1866

10.1158/1055-9965.epi-22-0043 | PMID 35700034 Get It

Abstract Background: Genome-wide association studies (GWAS) of multiple myeloma in populations of European ancestry (EA) identified and confirmed 24 susceptibility loci. For other cancers (e.g., colorectum and melanoma), risk loci have also been associated with patient survival. Methods: We explored the possible association of all the known risk variants and their polygenic risk score (PRS) with multiple myeloma overall survival (OS) in multiple populations of EA [the International Multiple Myeloma rESEarch (IMMEnSE) consortium, the International Lymphoma Epidemiology consortium, CoMMpass, and the German GWAS] for a total of 3,748 multiple myeloma cases. Cox proportional hazards regression was used to assess the association between each risk SNP with OS under the allelic and codominant models of inheritance. All analyses were adjusted for age, sex, country of origin (for IMMEnSE) or principal components (for the others) and disease stage (ISS). SNP associations were meta-analyzed. Results: SNP associations were meta-analyzed. From the meta-analysis, two multiple myeloma risk SNPs were associated with OS (P < 0.05), specifically POT1-AS1-rs2170352 [HR = 1.37; 95% confidence interval (CI) = 1.09–1.73; P = 0.007] and TNFRSF13B-rs4273077 (HR = 1.19; 95% CI = 1.01–1.41; P = 0.04). The association between the combined 24 SNP MM-PRS and OS, however, was not significant. Conclusions: Overall, our results did not support an association between the majority of multiple myeloma risk SNPs and OS. Impact: This is the first study to investigate the association between multiple myeloma PRS and OS in multiple myeloma.
Pulmonary Artery Angiomatoid Fibrous Histiocytoma Mimicking a Large Pulmonary Embolism
Haug, Logan P. , Zarka, Matthew A., D’Cunha, Jonathan, Downey, Francis X. , Seetharam, ­Mahesh , Yang, Ming

Mayo Clinic

Clinical Nuclear Medicine | June 13, 2022 | Volume: 47 | Issue: 12 | Pages: e738-e739

10.1097/rlu.0000000000004306 | PMID 35695721 Get It

Abstract A 39-year-old man presented with progressive dyspnea and lower extremity edema. Doppler ultrasound demonstrated bilateral leg partially occluded venous thromboses. A V/Q scan revealed a mismatched perfusion defect involving the entire right middle and lower lobes. Subsequent CT pulmonary angiogram revealed a mass lesion occluding the right interlobar pulmonary artery. Endobronchial ultrasound–guided fine-needle aspiration of the mass was concerning for neoplasm. 18 F-FDG PET/CT demonstrated marked hypermetabolism of the mass lesion. Patient underwent transmediastinal right pneumonectomy with histopathologic diagnosis of pulmonary artery angiomatoid fibrous histiocytoma, a rare etiology mimicking large pulmonary artery embolism.
APOE ε4 influences medial temporal atrophy and tau deposition in atypical Alzheimer's disease
Singh, Neha Atulkumar , Tosakulwong, Nirubol , Graff‐Radford, Jonathan , Pham, Nha Trang Thu, Sintini, Irene , Weigand, Stephen D. , Senjem, Matthew L. , Carrasquillo, Minerva M. , Ertekin‐Taner, Nilüfer , Lowe, Val J. , Josephs, Keith A. , Whitwell, Jennifer L. , Senjem, Matthew L , Singh, Neha Atulkumar , Machulda, Mary M. , Schwarz, Christopher G. , Carrasquillo, Minerva M. , Jack, Clifford R.

Mayo Clinic

Alzheimer's & Dementia | June 12, 2022 | Volume: 19 | Issue: 3 | Pages: 784-796

10.1002/alz.12711 | PMID 35691047 Get It

AbstractIntroductionApolipoprotein E (APOE) ε4 is an important genetic risk factor for typical Alzheimer's disease (AD), influencing brain volume and tau burden. Little is known about its influence in atypical presentations of AD.MethodsAn atypical AD cohort of 140 patients diagnosed with either posterior cortical atrophy or logopenic progressive aphasia underwent magnetic resonance imaging and positron emission tomography. Linear mixed effects models were fit to assess the influence of APOE ε4 on cross‐sectional and longitudinal regional metrics.ResultsAt baseline, APOE ε4 carriers had smaller hippocampal and amygdala volumes and greater tau standardized uptake volume ratio in the hippocampus and entorhinal cortex compared to non‐carriers while longitudinally, APOE ε4 non‐carriers showed faster rates of atrophy and tau accumulation in the entorhinal cortex, with faster tau accumulation in the hippocampus.DiscussionAPOE ε4 influences patterns of neurodegeneration and tau deposition and was associated with more medial temporal involvement, although there is evidence that non‐carriers may be catching up over time.
Cancer Therapy Approval Timings, Review Speed, and Publication of Pivotal Registration Trials in the US and Europe, 2010-2019
Desai, Aakash , Krell, Jonathan , Desai, Aakash P , Lythgoe, Mark Peter , Gyawali, Bishal , Savage, Philip M. , Warner, Jeremy L. , Khaki, Ali Raza

Mayo Clinic

JAMA Network Open | June 10, 2022 | Volume: 5 | Issue: 6 | Pages: e2216183

10.1001/jamanetworkopen.2022.16183 | PMID 35687337 Get It